wallstreet:online
41,35EUR | +0,05 EUR | +0,12 %
DAX+0,26 % EUR/USD-0,06 % Gold+0,26 % Öl (Brent)+0,19 %

Nordic Nanovector ASA Increased Share Capital Following Exercise of Employee Share Options

Nachrichtenquelle: PR Newswire (engl.)
19.09.2019, 16:11  |  258   |   |   

OSLO, Norway, Sept. 19, 2019 /PRNewswire/ -- One former employee and a participant in the Company's previous share option program, not being a primary insider, has exercised a total number of 5,775 options through exercise of a corresponding number of free-standing warrants. The options are exercised at a strike price of NOK 14.24. Each free-standing warrant gives the right to receive one share in the Company.

The share capital increase related to the exercise of the options has been duly registered in the Norwegian Register of Business Enterprises. Following the registration, the Company's share capital is NOK 11,023,894.20 divided into 55,119,471 shares, each with a nominal value of NOK 0.20.

For further information, please contact: 

IR enquiries 

Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com  

International Media Enquiries  

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com  

About Nordic Nanovector  

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin in core markets. Further information can be found at www.nordicnanovector.com 

Forward-looking statements

This press release contains certain forward-looking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--increased-share-capital-following-exercise-of-employee-share-options,c2909309

Diesen Artikel teilen
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
USDCapCapitalNanoNOK


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel
Aus der Redaktion
Aus der Community